Small Caps Rise Amid Biotech and Consumer Goods Announcements

OKYO Pharma's lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting. NEXE Innovations reported higher revenue and improved cost controls in its second quarter of fiscal 2026. Protalix Biotherapeutics received a positive opinion from the European Medicines Agency for an expanded dosing regimen for its treatment, Elfabrio. Delivra Health Brands appointed John Barrett as a director, adding a former senior executive from major consumer goods companies. Allergy Therapeutics strengthened its management team with the appointment of Helge Weiner-Trapness as chief strategy officer and executive director.